07:00 , Oct 29, 2012 |  BC Week In Review  |  Company News

Qiagen, Bio*One Capital Pte. Ltd. sales and marketing update

Dx Assays Pte. Ltd., a JV between Qiagen and Bio*One Capital, launched its fee-for-service companion diagnostic partnership initiative. The initiative will provide biomarker discovery and assay validation services as well as assistance in manufacturing and...
08:00 , Feb 14, 2011 |  BioCentury  |  Politics, Policy & Law

BIO's compendium of ideas

The Biotechnology Industry Organization plans to release a report this week outlining potential "game changing" options for the biotech industry as part of a strategic planning exercise that will lead to the development of legislative...
07:00 , Jul 19, 2010 |  BC Week In Review  |  Financial News

MerLion completes venture financing

MerLion Pharmaceuticals Pte. Ltd. , Singapore   Business: High throughput screening   Date completed: 7/13/10   Type: Venture financing   Raised: $7 million   Investors: Aravis Venture; Aurelia Private Equity GmbH; Bio*One Capital; Heidelberg Innovation;...
07:00 , Jun 14, 2010 |  BC Week In Review  |  Financial News

Inotek completes venture financing

Inotek Pharmaceuticals Corp. , Lexington, Mass.   Business: Ophthalmic, Renal, Autoimmune   Date completed: 6/10/10   Type: Venture financing   Raised: $18 million   Investors: Devon Park Bioventures; Rho Ventures; Care Capital; Pitango; MedImmune Ventures;...
08:00 , Dec 14, 2009 |  BioCentury  |  Finance

Ebb & Flow

Investors in oncology company Gloucester Pharmaceuticals Inc. are looking at a 3.5X-6.5X return on an acquisition by Celgene Corp. (NASDAQ: CELG), making it a model for how to execute in-licensing and keep costs under control....
08:00 , Dec 7, 2009 |  BC Week In Review  |  Financial News

Forma completes venture financing

Forma Therapeutics Inc. , Cambridge, Mass.   Business: Computational chemistry/biology   Date completed: 12/1/09   Type: Venture financing   Raised: $25.5 million   Investors: Lilly Ventures; Novartis Option Fund; Bio*One Capital; Cubist Pharmaceuticals Inc.  ...
01:17 , Dec 2, 2009 |  BC Extra  |  Financial News

Forma raises $25.5 million

Forma Therapeutics Inc . (Cambridge, Mass.) raised $25.5 million in a series B round led by new investor Lilly Ventures. Existing investors Novartis Option Fund and Bio*One Capital also participated. Partner Cubist Pharmaceuticals Inc ....
07:00 , Oct 12, 2009 |  BC Week In Review  |  Financial News

Inviragen completes venture financing

Inviragen Inc. , Fort Collins, Colo.   Business: Infectious   Date completed: 10/6/09   Type: Venture financing   Raised: $15 million   Investors: Charter Life Sciences; Venture Investors LLC; Bio*One Capital; Phillip Private Equity  ...
08:00 , Jan 26, 2009 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Forma Therapeutics Inc. Cambridge, Mass. Technology: Small molecule cancer therapeutics Disease focus: Cancer and infectious diseases Clinical status: Preclinical Founded: 2007 by Stuart Schreiber, Todd Golub, Michael Foley, Nikolai Kley and Steven Tregay University collaborators:...
01:42 , Oct 21, 2008 |  BC Extra  |  Financial News

S*BIO raises $26 million

S*BIO (Singapore) raised US$26 million in a series B round co-led by existing investor Bio*One Capital and new investor Aravis Venture. New investors Lacuna Apo BioTech Fund, which is advised by Adamant Biomedical Investments, and...